Summit Therapeutics Inc. (SMMT)
23.70
0.18 (0.77%)
At close: Jan 28, 2025, 1:55 PM
Company Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.
It conducts clinical programs focusing on Clostridioides difficile infection (CDI).
The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae.
The company was founded in 2003 and is based in Cambridge, Massachusetts.
Summit Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 5, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | Robert W. Duggan |
Contact Details
Address: One Broadway Cambridge, Massachusetts United States | |
| Website | https://www.summittxinc.com |
Stock Details
| Ticker Symbol | SMMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001599298 |
| CUSIP Number | 86627T108 |
| ISIN Number | US86627T1088 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President & Director |
| Robert W. Duggan | Co-Chief Executive Officer & Executive Chairman |
| Manmeet Singh Soni CPA | Chief Operating Officer, Chief Financial Officer & Director |
| Bhaskar Anand | Chief Accounting Officer & Head of Finance |
| Dave Gancarz | Chief Business & Strategy Officer |
| Divya Chari | Head of Global Clinical Operations |
| Dr. Betty Y. Chang Ph.D. | Head of Research, Oncology & Inflammation |
| Dr. Fong Clow | Chief Biometrics Officer |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Shelley D. Spray | Chief Education & Brand Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 24, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 4 | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |